jurgenfr Shares of Sage Therapeutics ( NASDAQ: SAGE ) fell 18% post-market after the company released its Q3 earnings report and said further development of its drug zuranolone for major depressive disorder has been scrapped. Sage’s ( SAGE ) Q3 earnings were largely in line.
Back to Health Page
